The briefing
New research in The Lancet Psychiatry found GLP-1 receptor agonist treatment was associated with lower rates of psychiatric hospitalization and emergency visits among people with both schizophrenia and type 2 diabetes. The findings suggest these medications may offer mental health benefits alongside metabolic care.
Original headline
Schizophrenia and type 2 diabetes are linked, but GLP-1s could help manage the risks